Atlas Trials

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Clinical trial NCT01269385 · COMPLETED

Trial details

NCT number
NCT01269385
Sponsor
Mayo Clinic
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
B-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic Leukemia
Start date
2011-01-01
Primary completion
2014-06-01
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.